Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease

Basic Res Cardiol. 2017 May;112(3):32. doi: 10.1007/s00395-017-0619-0. Epub 2017 Apr 24.

Abstract

Ischemic heart disease is the main cause of death worldwide and is accelerated by increased levels of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a potent circulating regulator of LDL-C through its ability to induce degradation of the LDL receptor (LDLR) in the lysosome of hepatocytes. Only in the last few years, a number of breakthroughs in the understanding of PCSK9 biology have been reported illustrating how PCSK9 activity is tightly regulated at several levels by factors influencing its transcription, secretion, or by extracellular inactivation and clearance. Two humanized antibodies directed against the LDLR-binding site in PCSK9 received approval by the European and US authorities and additional PCSK9 directed therapeutics are climbing up the phases of clinical trials. The first outcome data of the PCSK9 inhibitor evolocumab reported a significant reduction in the composite endpoint (cardiovascular death, myocardial infarction, or stroke) and further outcome data are awaited. Meanwhile, it became evident that PCSK9 has (patho)physiological roles in several cardiovascular cells. In this review, we summarize and discuss the recent biological and clinical data on PCSK9, the regulation of PCSK9, its extra-hepatic activities focusing on cardiovascular cells, molecular concepts to target PCSK9, and finally briefly summarize the data of recent clinical studies.

Keywords: LDL; LDL receptor; oxLDL.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / metabolism*
  • Humans
  • Proprotein Convertase 9 / metabolism*
  • Receptors, LDL / metabolism

Substances

  • Receptors, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9